Properties (60)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
2021
$3.1 billion Novo Nordisk |
| gptkbp:CEO |
gptkb:Douglas_Fambrough
|
| gptkbp:clinicalTrials |
Phase 1
Phase 2 Phase 3 multiple drug candidates ongoing studies biopharmaceutical company multiple candidates in development completed studies RNAi therapeutics planned studies |
| gptkbp:collaborations |
gptkb:University_of_Massachusetts
gptkb:AstraZeneca gptkb:Alnylam_Pharmaceuticals gptkb:Harvard_University gptkb:Regeneron_Pharmaceuticals gptkb:MIT gptkb:Eli_Lilly_and_Company |
| gptkbp:employeeCount |
over 100
|
| gptkbp:focus |
RNA interference
|
| gptkbp:founded |
2006
|
| gptkbp:founder |
gptkb:Douglas_Fambrough
|
| gptkbp:funding |
grants
public offerings private placements |
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dicerna Pharmaceuticals
|
| gptkbp:investmentFocus |
research funding
strategic partnerships Venture capital firms development funding |
| gptkbp:market |
approximately $1 billion
|
| gptkbp:partnerships |
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb |
| gptkbp:patentCitation |
RNA interference technology
|
| gptkbp:platforms |
GalXC
|
| gptkbp:publications |
numerous peer-reviewed articles
|
| gptkbp:research_areas |
cancer
rare diseases metabolic diseases |
| gptkbp:research_focus |
gene silencing
therapeutics for autoimmune diseases therapeutics for infectious diseases therapeutics for cardiovascular diseases therapeutics for metabolic disorders therapeutics for neurological diseases therapeutics for liver diseases |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
DRNA
|
| gptkbp:supplyChain |
gptkb:DCR-PH1
DCR-HBVS DCR-MYC |
| gptkbp:supportRole |
experts in clinical trials
experts in drug development experts in RNA technology |
| gptkbp:website |
www.dicerna.com
|